September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Ardem Patapoutian: Excited to Join the Scientific Advisory Board of Stratus Therapeutics
Sep 7, 2025, 10:30

Ardem Patapoutian: Excited to Join the Scientific Advisory Board of Stratus Therapeutics

Ardem Patapoutian, Professor at The Scripps Research Institute, Nobel Prize in Physiology or Medicine 2021, shared a post by Stratus Therapeutics, adding:

“I just joined the SAB of Stratus Therapeutics.  I love highlighting how basic, curiosity-driven science can translate into unexpected, clinically relevant directions. Stratus is developing a cell therapy based on the finding that hematopoietic stem cells can be generated by stretching induced pluripotent stem cells. In culture, this is achieved with Yoda1, a PIEZO1 agonist, but the actual product is the cells themselves, aimed at restoring the blood and immune systems in patients without a matched donor. Go science!

And… in the “small world” category, Stratus CSO is Michael Cooke, a colleague from my Genomics Institute of the Novartis Research Foundation days in the early 2000s.

Read further.”

Quoting Stratus Therapeutics‘s post:

“We’re thrilled to welcome Nobel Laureate Dr. Ardem Patapoutian to the Stratus Therapeutics Scientific Advisory Board!

Dr. Patapoutian’s groundbreaking discovery of the PIEZO1 and PIEZO2 receptors earned him the 2021 Nobel Prize in Physiology or Medicine. This research laid the scientific foundation for the Stratus PRIME™ HSPC platform and the development of ST-101, our lead off-the-shelf hematopoietic stem cell (HSC) therapy. Dr. Patapoutian’s insights into mechanosensitive ion channels have transformed how we understand touch, pressure, and proprioception and now, they’re helping to shape a new future for immune and blood system replacement. As we move closer to the clinic, Dr. Patapoutian’s continued leadership in sensory biology and translational science will be invaluable.

Welcome aboard Dr. Ardem Patapoutian.

Read more.”

More from Ardem Patapoutian on OncoDaily.